Trial NCT04501978
Publication ACTIV-3/TICO Study Group, Ann Intern Med (2022) (published paper)
Dates: 2021-06-11 to 2021-11-15
Funding: Mixed (U.S. Operation Warp Speed program; the National Institute of Allergy and Infectious Diseases and Leidos Biomedical Research for the INSIGHT Network; the National Heart, Lung, and Blood Institute and the Research Triangle Institute for the Prevention and Early Treatment of Acute Lung Injury Network and the Cardiothoracic Surgical Trials Network; the U.S. Department of Veterans Affairs; the governments of Denmark (National Research Foundation), Australia (National Health and Medical Research Council), the United Kingdom (Medical Research Council), and Singapore (National Medical Research Council); National Institutes of Health and National Cancer Institute. Trial medications were donated by Molecular Partners (ensovibep) and Gilead Sciences (remdesivir). The funding organizations had no direct involvement in the decisions related to the trial or the drafting or revision of the manuscript.)
Conflict of interest: Yes